The relevance and role of vascular endothelial growth factor C, matrix metalloproteinase-2 and E-cadherin in epithelial ovarian cancer.
We investigated the correlation of vascular endothelial growth factor C, matrix metalloproteinase-2, E-cadherin to explore mechanisms of vascular endothelial growth factor C in the metastasis of ovarian cancer and the relationship of prognosis. We applied immunohistochemistry to investigate the expression of vascular endothelial growth factor C, matrix metalloproteinase-2 and E-cadherin in ovarian tissues of 227 patients. We adopted Pearson chi-square test, Spearman correlation coefficient, univariate analysis, multivariate analysis, and Kaplan-Meier method. The positive rate of vascular endothelial growth factor C, matrix metalloproteinase-2 and E-cadherin in ovarian cancer was higher than that in borderline and benign tumor (P < 0.01). Vascular endothelial growth factor C was positively correlated with matrix metalloproteinase-2 (r = 0.665, P < 0.01) while negatively with E-cadherin(r = -0.185, P < 0.05). Univariate analysis showed clinical stage, pathologic grade, lymphatic metastasis, residual disease, chemotherapy, ascites, vascular endothelial growth factor C, and matrix metalloproteinase-2-influenced survival time (P < 0.05). In Cox multivariate analysis, all the aforementioned factors were found to be independent prognostic factors except pathologic grade. Vascular endothelial growth factor C was a new target to assess the prognosis of ovarian cancer. The expression of vascular endothelial growth factor C in ovarian cancer was related to matrix metalloproteinase-2 and E-cadherin.
Department of Gynecology, The Third Affiliated Hospital of Harbin Medical University, 150040 Harbin, China.
Ke-Jin
KJ
Huang
Li-Hua
LH
Sui
D014408:Biomarkers, Tumor / Q000032:analysis; D015820:Cadherins / Q000096:biosynthesis*; D000077216:Carcinoma, Ovarian Epithelial; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D020778:Matrix Metalloproteinase 2 / Q000096:biosynthesis*; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D016016:Proportional Hazards Models; D042582:Vascular Endothelial Growth Factor C / Q000096:biosynthesis*
D014408:Biomarkers, Tumor; D015820:Cadherins; C467486:VEGFC protein, human; D042582:Vascular Endothelial Growth Factor C; C522361:MMP2 protein, human; D020778:Matrix Metalloproteinase 2
Lab Invest. 2001 Dec;81(12):1729-34
11742043
Int J Gynecol Cancer. 2007 Jan-Feb;17(1):68-75
17291234
Recent Prog Horm Res. 2000;55:15-35; discussion 35-6
11036931
Br J Cancer. 2007 Feb 26;96(4):541-5
17164762
Oncology. 2006;71(1-2):102-10
17341890
Int J Oncol. 2008 Mar;32(3):557-64
18292932
Gynecol Oncol. 2000 Nov;79(2):251-5
11063653
CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
20610543
Clin Cancer Res. 2005 May 1;11(9):3225-32
15867217
Pancreas. 2001 Apr;22(3):285-92
11291931
Gynecol Oncol. 2006 Sep;102(3):432-9
16860852
Int J Biol Markers. 2010 Jan-Mar;25(1):38-45
20306451
Eur J Cancer. 2000 Aug;36(13 Spec No):1621-30
10959048
Ann Oncol. 2005 Jul;16(7):1116-22
15928071
Oncology. 2006;71(3-4):204-11
17641542
J Obstet Gynaecol Can. 2010 Jun;32(6):580-586
20569539
Cancer Res. 2009 Jan 1;69(1):349-57
19118020
Am J Pathol. 2008 Oct;173(4):938-48
18772335
Cancer Res. 2004 Jan 15;64(2):652-8
14744781
Minerva Ginecol. 2004 Dec;56(6):547-56
15729207
Gynecol Oncol. 2004 Feb;92(2):559-67
14766248